$KPTI
Karyopharm Therapeutics Inc.

2017 Q4 Form 10-Q Financial Statement

#000156459017021223 Filed on November 02, 2017

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2016 Q3
Revenue $1.534M $0.00 $48.00K
YoY Change 3163.83% -100.0% -36.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.150M $5.820M $5.900M
YoY Change -5.96% -1.36% 23.95%
% of Gross Profit
Research & Development $34.83M $25.24M $19.89M
YoY Change 68.51% 26.86% -23.26%
% of Gross Profit
Depreciation & Amortization $170.0K $180.0K $180.0K
YoY Change -5.56% 0.0% 5.88%
% of Gross Profit
Operating Expenses $40.99M $31.06M $25.79M
YoY Change 50.62% 20.41% -15.95%
Operating Profit -$39.45M -$31.06M -$25.74M
YoY Change 45.23% 20.64% -15.9%
Interest Expense $430.0K $450.0K $310.0K
YoY Change 19.44% 45.16% 29.17%
% of Operating Profit
Other Income/Expense, Net $421.0K $428.0K $317.0K
YoY Change 14.09% 35.02% 33.76%
Pretax Income -$39.03M -$30.63M -$25.43M
YoY Change 45.63% 20.46% -16.28%
Income Tax $10.00K $13.00K
% Of Pretax Income
Net Earnings -$39.04M -$30.64M -$25.43M
YoY Change 44.94% 20.51% -16.29%
Net Earnings / Revenue -2544.98% -52968.75%
Basic Earnings Per Share
Diluted Earnings Per Share -$802.1K -$650.0K -$690.7K
COMMON SHARES
Basic Shares Outstanding 47.18M 47.14M shares 35.99M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q4 2017 Q3 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $146.5M $119.4M $126.8M
YoY Change 13.02% -5.84% -35.04%
Cash & Equivalents $69.00M $54.45M $43.91M
Short-Term Investments $77.47M $65.00M $82.90M
Other Short-Term Assets $2.000M $2.300M $3.400M
YoY Change -4.76% -32.35% 9.68%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $148.4M $121.7M $130.3M
YoY Change 12.75% -6.58% -34.33%
LONG-TERM ASSETS
Property, Plant & Equipment $2.185M $2.304M $2.991M
YoY Change -22.95% -22.97% -18.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $29.40M $39.50M $49.60M
YoY Change -35.24% -20.36% 44.19%
Other Assets $300.0K $300.0K $299.0K
YoY Change -40.0% 0.33% 475.0%
Total Long-Term Assets $31.87M $42.09M $53.37M
YoY Change -34.62% -21.14% 38.17%
TOTAL ASSETS
Total Short-Term Assets $148.4M $121.7M $130.3M
Total Long-Term Assets $31.87M $42.09M $53.37M
Total Assets $180.3M $163.8M $183.6M
YoY Change -0.05% -10.81% -22.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.665M $1.890M $2.193M
YoY Change 19.24% -13.82% -51.99%
Accrued Expenses $21.45M $17.72M $12.31M
YoY Change 88.74% 43.92% 29.99%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $49.47M $21.16M $14.95M
YoY Change 200.24% 41.49% 3.55%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.400M $1.400M $1.700M
YoY Change -17.65% -17.65% -10.53%
Total Long-Term Liabilities $1.400M $1.400M $1.700M
YoY Change -17.65% -17.65% -10.53%
TOTAL LIABILITIES
Total Short-Term Liabilities $49.47M $21.16M $14.95M
Total Long-Term Liabilities $1.400M $1.400M $1.700M
Total Liabilities $50.83M $22.60M $16.69M
YoY Change 180.18% 35.38% 1.9%
SHAREHOLDERS EQUITY
Retained Earnings -$495.3M -$456.3M -$339.2M
YoY Change 35.3% 34.53% 49.1%
Common Stock $625.0M $597.6M $506.1M
YoY Change 18.24% 18.07% 12.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $129.5M $141.2M $166.9M
YoY Change
Total Liabilities & Shareholders Equity $180.3M $163.8M $183.6M
YoY Change -0.05% -10.81% -22.51%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2016 Q3
OPERATING ACTIVITIES
Net Income -$39.04M -$30.64M -$25.43M
YoY Change 44.94% 20.51% -16.29%
Depreciation, Depletion And Amortization $170.0K $180.0K $180.0K
YoY Change -5.56% 0.0% 5.88%
Cash From Operating Activities -$5.540M -$21.75M -$20.33M
YoY Change -72.3% 6.98% -19.74%
INVESTING ACTIVITIES
Capital Expenditures -$50.00K -$10.00K $0.00
YoY Change 150.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$2.850M $20.61M -$4.970M
YoY Change -142.99% -514.69% -111.12%
Cash From Investing Activities -$2.900M $20.60M -$4.980M
YoY Change -143.87% -513.65% -111.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 22.95M 160.0K 31.48M
YoY Change 19.28% -99.49% 78600.0%
NET CHANGE
Cash From Operating Activities -5.540M -21.75M -20.33M
Cash From Investing Activities -2.900M 20.60M -4.980M
Cash From Financing Activities 22.95M 160.0K 31.48M
Net Change In Cash 14.51M -990.0K 6.170M
YoY Change 148.03% -116.05% -67.96%
FREE CASH FLOW
Cash From Operating Activities -$5.540M -$21.75M -$20.33M
Capital Expenditures -$50.00K -$10.00K $0.00
Free Cash Flow -$5.490M -$21.74M -$20.33M
YoY Change -72.52% 6.94% -19.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 us-gaap Assets Current
AssetsCurrent
131636000
CY2017Q3 us-gaap Liabilities Current
LiabilitiesCurrent
21155000
CY2017Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2304000
CY2017Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
47180775
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54450000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16476000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49663000
CY2017Q3 us-gaap Short Term Investments
ShortTermInvestments
64956000
CY2017Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1441000
CY2016Q4 us-gaap Short Term Investments
ShortTermInvestments
79889000
CY2017Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
200000
CY2017Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2076000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2084000
CY2017Q3 us-gaap Assets Current
AssetsCurrent
121682000
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1666000
CY2017Q3 us-gaap Liabilities
Liabilities
22596000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Trading Symbol
TradingSymbol
KPTI
dei Entity Central Index Key
EntityCentralIndexKey
0001503802
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2836000
CY2017Q3 us-gaap Long Term Investments
LongTermInvestments
39498000
CY2016Q4 us-gaap Long Term Investments
LongTermInvestments
45434000
CY2017Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
289000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
479000
CY2017Q3 us-gaap Assets
Assets
163773000
CY2016Q4 us-gaap Assets
Assets
180385000
CY2017Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1890000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4751000
CY2017Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17715000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11362000
CY2017Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1050000
CY2017Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
298000
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
280000
CY2017Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
202000
CY2016Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
83000
CY2016Q4 us-gaap Liabilities
Liabilities
18142000
CY2017Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Period End Date
DocumentPeriodEndDate
2017-09-30
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
KARYOPHARM THERAPEUTICS INC.
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-366104000
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-456300000
CY2017Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-90000
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
141177000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
162243000
CY2017Q3 us-gaap Common Stock Value
CommonStockValue
5000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2017Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
597562000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
528617000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-274000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2017Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
163773000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
180385000
CY2017Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47154204
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41887829
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47154204
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41887829
CY2016Q3 us-gaap Revenue From Grants
RevenueFromGrants
48000
us-gaap Revenue From Grants
RevenueFromGrants
71000
us-gaap Revenue From Grants
RevenueFromGrants
107000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25237000
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19893000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
72440000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
66267000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5818000
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5897000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18717000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17407000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
31055000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
25790000
us-gaap Operating Expenses
OperatingExpenses
91157000
us-gaap Operating Expenses
OperatingExpenses
83674000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-31055000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-25742000
us-gaap Operating Income Loss
OperatingIncomeLoss
-91086000
us-gaap Operating Income Loss
OperatingIncomeLoss
-83567000
CY2017Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
454000
CY2016Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
311000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1266000
us-gaap Investment Income Interest
InvestmentIncomeInterest
926000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-26000
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-70000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
428000
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
317000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1196000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
925000
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30627000
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25425000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-89890000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-82642000
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13000
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36819329
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44974945
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25592000
kpti Deferred Financing Costs Included In Other Current Assets
DeferredFinancingCostsIncludedInOtherCurrentAssets
16000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-89760000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-82388000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.00
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
54000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-30640000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-25425000
us-gaap Net Income Loss
NetIncomeLoss
-89944000
us-gaap Net Income Loss
NetIncomeLoss
-82642000
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.28
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47141146
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36223324
CY2017Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
25000
CY2016Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-182000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
50000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
225000
CY2017Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
50000
CY2016Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
15000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
134000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
29000
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30565000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
539000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
537000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-903000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-839000
us-gaap Share Based Compensation
ShareBasedCompensation
15906000
us-gaap Share Based Compensation
ShareBasedCompensation
17157000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-18000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-412000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2867000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1659000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
6423000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1101000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1050000
kpti Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-207000
kpti Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-138000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-68179000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-64393000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
45000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
94033000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
140719000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
74017000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
122681000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
20009000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
17993000
kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
52323000
kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
31463000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
463000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
452000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
52786000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
31915000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
171000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
35000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4787000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-14450000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58358000
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43908000
kpti Deferred Financing Costs Included In Accounts Payable
DeferredFinancingCostsIncludedInAccountsPayable
40000
kpti Deferred Financing Costs Included In Accrued Expenses
DeferredFinancingCostsIncludedInAccruedExpenses
258000
kpti Deferred Financing Costs Included In Other Current Assets
DeferredFinancingCostsIncludedInOtherCurrentAssets
1883000
CY2017Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
133492000
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
163239000
CY2017Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
104559000
CY2017Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
10000
CY2017Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
115000
CY2017Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
104454000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
125478000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
39000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
194000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
125323000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1845000
CY2017Q3 kpti Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
13328000
CY2016Q4 kpti Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
6855000
CY2016Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
0
CY2017Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4688000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4681000
CY2017Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2384000
CY2017Q3 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
49
CY2016Q4 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
58
CY2017Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
81275000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
95949000
CY2017Q3 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
0
CY2017Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3129000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3476000
CY2017Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
955000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
480000
CY2017Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
303000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
551000
CY2014Q1 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
29933
CY2014Q1 kpti Number Of Additional Lease Terms Option To Renew
NumberOfAdditionalLeaseTermsOptionToRenew
1
CY2014Q1 kpti Lessee Leasing Arrangements Operating Leases Additional Extension Term
LesseeLeasingArrangementsOperatingLeasesAdditionalExtensionTerm
P5Y
CY2015Q1 kpti Operating Leases Allowance For Improvements
OperatingLeasesAllowanceForImprovements
1616000
CY2014Q1 us-gaap Security Deposit
SecurityDeposit
400000
CY2014Q1 kpti Estimated Future Security Deposit
EstimatedFutureSecurityDeposit
200000
CY2014Q4 kpti Additional Area Included In Operating Sublease After Amendment
AdditionalAreaIncludedInOperatingSubleaseAfterAmendment
16234
CY2014Q4 kpti Operating Lease Property Offer To Lease Additional Space Area Covered Under Amended Agreement
OperatingLeasePropertyOfferToLeaseAdditionalSpaceAreaCoveredUnderAmendedAgreement
27701
CY2014Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
3681
CY2014Q4 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P5Y
CY2014Q4 kpti Operating Lease Scheduled Rent Payments Due
OperatingLeaseScheduledRentPaymentsDue
374000
CY2014Q4 kpti Operating Lease Scheduled Rent Payments Due
OperatingLeaseScheduledRentPaymentsDue
427000
CY2017Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
296000
CY2016Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
280000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
894000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
859000

Files In Submission

Name View Source Status
0001564590-17-021223-index-headers.html Edgar Link pending
0001564590-17-021223-index.html Edgar Link pending
0001564590-17-021223.txt Edgar Link pending
0001564590-17-021223-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
kpti-10q_20170930.htm Edgar Link pending
kpti-20170930.xml Edgar Link completed
kpti-20170930.xsd Edgar Link pending
kpti-20170930_cal.xml Edgar Link unprocessable
kpti-20170930_def.xml Edgar Link unprocessable
kpti-20170930_lab.xml Edgar Link unprocessable
kpti-20170930_pre.xml Edgar Link unprocessable
kpti-ex311_9.htm Edgar Link pending
kpti-ex312_7.htm Edgar Link pending
kpti-ex321_8.htm Edgar Link pending
kpti-ex322_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending